The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 19, 2016

Filed:

Jun. 16, 2011
Applicants:

Cyril Y. Bowers, New Orleans, LA (US);

David H. Coy, New Orleans, LA (US);

Simon J. Hocart, New Orleans, LA (US);

Gloria S. Tannenbaum, Hampstead, CA;

Inventors:

Cyril Y. Bowers, New Orleans, LA (US);

David H. Coy, New Orleans, LA (US);

Simon J. Hocart, New Orleans, LA (US);

Gloria S. Tannenbaum, Hampstead, CA;

Assignees:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/08 (2006.01); A61K 38/10 (2006.01); A61K 38/16 (2006.01); A61K 38/22 (2006.01); C07K 14/575 (2006.01); A61K 38/00 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); A61K 38/04 (2006.01); C07K 7/08 (2006.01); A61K 38/03 (2006.01); C07K 14/475 (2006.01); A61K 38/25 (2006.01); C07K 5/062 (2006.01); C07K 14/60 (2006.01); C07K 5/08 (2006.01); C07K 7/06 (2006.01); C07K 14/00 (2006.01); C07K 14/72 (2006.01);
U.S. Cl.
CPC ...
C07K 7/08 (2013.01); A61K 38/03 (2013.01); A61K 38/04 (2013.01); A61K 38/08 (2013.01); A61K 38/10 (2013.01); A61K 38/16 (2013.01); A61K 38/25 (2013.01); C07K 5/06026 (2013.01); C07K 5/08 (2013.01); C07K 7/06 (2013.01); C07K 14/00 (2013.01); C07K 14/475 (2013.01); C07K 14/60 (2013.01); C07K 14/723 (2013.01); A61K 38/00 (2013.01);
Abstract

The present invention provides novel peptides that can modulate the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and sub-types, isoforms and variants thereof). These peptides are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperpro-liferative disorders.


Find Patent Forward Citations

Loading…